

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person Greenberg Robert J.		2. Issuer Name and Ticker or Trading Symbol SECOND SIGHT MEDICAL PRODUCTS INC [EYES]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) CHIEF EXECUTIVE OFFICER	
(Last) 12744 SAN FERNANDO ROAD, BLDG. 3	(First) (Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/02/2015			
(Street) SYLMAR, CA 91342	(City) (State) (Zip)	4. If Amendment, Date Original Filed (Month/Day/Year)		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)			
COMMON STOCK	06/02/2015		M		78,153 (1)	A \$ 4.75	301,187	D	
COMMON STOCK	06/02/2015		F		26,586 (2)	D \$ 13.96 (3)	275,231	D	
COMMON STOCK	06/02/2015		S		78,153	D \$ 13.96 (4)	197,078	D	
COMMON STOCK	06/03/2015		M		71,847 (5)	A \$ 4.75	268,925	D	
COMMON STOCK	06/03/2015		F		24,167 (6)	D \$ 14.12 (3)	244,758	D	
COMMON STOCK	06/03/2015		S		71,847	D \$ 14.12 (7)	172,911	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Option	\$ 4.75	06/02/2015		M		78,153		(8)	09/01/2015	Common Stock	78,153	\$ 0	71,847	D	
Option	\$ 4.75	06/03/2015		M		71,847		(8)	09/01/2015	Common Stock	71,847	\$ 0	0	D	
Option	\$ 4.25							(8)	01/01/2017	Common Stock	125,000		125,000	D	
Option	\$ 4.75							(8)	01/01/2016	Common Stock	17,969		17,969	D	
Option	\$ 5							(8)	05/01/2016	Common Stock	8,223		8,223	D	
Option	\$ 5							(8)	01/01/2017	Common Stock	30,625		30,625	D	

Option	\$ 5							(8)	02/01/2018	Common Stock	23,750		30,625	D
Option	\$ 5							(8)	11/01/2018	Common Stock	150,000		150,000	D
Option	\$ 5							(8)	02/01/2019	Common Stock	33,750		33,750	D
Option	\$ 5							(8)	02/01/2020	Common Stock	53,125		53,125	D
Option	\$ 5							(8)	02/01/2020	Common Stock	50,625		50,625	D
Option	\$ 5							(8)	03/01/2021	Common Stock	41,563		41,563	D
Option	\$ 5							(8)	03/01/2022	Common Stock	29,063		29,063	D
Option	\$ 5							(8)	04/01/2024	Common Stock	11,719		11,719	D

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Greenberg Robert J. 12744 SAN FERNANDO ROAD, BLDG. 3 SYLMAR, CA 91342	X		CHIEF EXECUTIVE OFFICER	

Signatures

/s/ Robert J. Greenberg		06/04/2015
<small>Signature of Reporting Person</small>		<small>Date</small>

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Dr. Greenberg exercised 78,153 vested options reported as Option(C) on Form 3 filed with the SEC on November 18, 2014.

(2) Dr. Greenberg tendered 26,586 shares of common stock to the Company in accordance with Rule 16b-3.

(3) The fair market value on the day of the exercise.

(4) The price reported in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from \$13.56 to \$14.35, inclusive. The broker remitted \$277,224 to the Company to cover withholding obligations. The reporting person undertakes to provide to the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. These transactions were effected pursuant to planned sales under lock-up agreement entered into at the time of EYES IPO in November 2014, as approved by Board of EYES and the IPO underwriter and as further disclosed in the Company's final prospectus dated November 20, 2014.

(5) Dr. Greenberg exercised 71,847 vested options reported as Option(C) on Form 3 filed with the SEC on November 18, 2014.

(6) Dr. Greenberg tendered 24,167 shares of common stock to the Company in accordance with Rule 16b-3.

(7) The price reported in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from \$13.50 to \$14.64, inclusive. The broker remitted \$351,333 to the Company to cover withholding obligations. The reporting person undertakes to provide to the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. These transactions were effected pursuant to planned sales under lock-up agreement entered into at the time of EYES IPO in November 2014, as approved by Board of EYES and the IPO underwriter and as further disclosed in the Company's final prospectus dated November 20, 2014.

(8) These are vested employee options currently exercisable.

Remarks:

Excludes unvested employee options covering 490,752 shares, not exercisable for over 60 days from this date. Sales were automatically effected pursuant to 10b5-1 trading plan and trades reported on this Form 4 constitute the final trades pursuant to this 10b5-1 plan adopted by the reporting person.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.